What the FDA labels say about taking them together
Bictegravir/emtricitabine/tenofovir alafenamide and sucralfate
Bictegravir/emtricitabine/tenofovir alafenamide's FDA label of April 30, 2024 names sucralfate in its drug interactions section; the sucralfate labels PlainMeds reads (2) do not name bictegravir/emtricitabine/tenofovir alafenamide. The bictegravir/emtricitabine/tenofovir alafenamide label: “Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Routine administration of BIKTARVY together with, or 2 hours after, antacids containing Al/Mg …”
Check it at the source: the bictegravir/emtricitabine/tenofovir alafenamide FDA label on DailyMed (effective April 30, 2024, A-S Medication Solutions); the sucralfate FDA label on DailyMed (effective September 2, 2026, Preferred Pharmaceuticals Inc.).
What does the bictegravir/emtricitabine/tenofovir alafenamide label say about sucralfate?
Bictegravir/emtricitabine/tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Medications or oral supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives Sucralfate Buffered medications; Effect on Concentration ↑ = Increase, ↓ = Decrease.: ↓ BIC; Clinical Comment: Antacids containing Al/Mg: BIKTARVY can be taken at least 2 hours before or 6 hours after taking antacids containing Al/Mg. Routine administration of BIKTARVY together with, or 2 hours after, antacids containing Al/Mg is not recommended. Supplements or Antacids containing Calcium or Iron: BIKTARVY and supplements or antacids containing calcium or iron can be taken together with food. …
Source: FDA drug label (Biktarvy), NDA210251 (Gilead Sciences Inc), as published by A-S Medication Solutions, effective April 30, 2024 (SPL set 0476d7eb-1024-4821-bbe7-abaacfda32a2), via openFDA; the full label on DailyMed
What does the sucralfate label say about bictegravir/emtricitabine/tenofovir alafenamide?
Sucralfate's label (effective September 2, 2026) and its 1 other brand-application label do not name bictegravir/emtricitabine/tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Sucralfate), NDA018333 (Abbvie), as published by Preferred Pharmaceuticals Inc., effective September 2, 2026 (SPL set 536b8c00-13ab-4397-a754-63a1c92bf883), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bictegravir/emtricitabine/tenofovir alafenamide | Sucralfate | |
|---|---|---|
| Labeled for | HIV | Acid reflux and ulcers |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $136.73 per tablet 50-200-25 mg tablet | $0.173 per tablet 1 g tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once